Compare Manulife Financial Corporation (MFC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Novo Nordisk A/S — how do they compare? Manulife Financial Corporation trades at $43.58 (market cap $69.48B), while Novo Nordisk A/S trades at $38.26 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.4× Manulife Financial Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and Novo Nordisk A/S for 116 Days on average.
| MFC | NVO | |
|---|---|---|
Market Cap | $69.48B | $165.31B |
Volume | 1,347,508 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $44.77 | $63.98 |
52-Week Low | $31.64 | $35.29 |
Typical Hold Time | 119 Days | 116 Days |
Enterprise Value | $64.75B | $179.56B |
Dividend Yield | 3.23% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $41.67, down 2.94% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and executive appointments signal confidence in long-term strategy.
MFC presents a mixed outlook with strong profitability metrics (11.7% net margin, 13.88% ROE) and analyst consensus favoring Buy ratings (57%), but faces technical headwinds and premium valuation concerns. The stock trades above the $34.24 consensus target, suggesting limited near-term upside despite operational strength and dividend stability.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
